NYSEAMERICAN:PFNX Pfenex (PFNX) Stock Price, News & Analysis $12.75 0.00 (0.00%) As of 10/1/2020 Add Compare Share Share Stock Analysis Stock Analysis About Pfenex Stock (NYSEAMERICAN:PFNX) Get Pfenex alerts:Sign Up Key Stats Today's Range$12.75▼$12.7550-Day Range$12.75▼$12.7552-Week Range$5.26▼$14.00VolumeN/AAverage Volume503,865 shsMarket Capitalization$437.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pfenex was a biotechnology company that developed recombinant proteins and biosimilar medicines using its Pfenex Expression Technology platform. Its work focused on producing complex proteins for pharmaceutical applications. The company advanced PF708, a teriparatide injection later marketed as Bonsity, and collaborated with Pfizer on PF-06439535, a bevacizumab biosimilar marketed as Zirabev. These products were developed for markets including the United States and other countries through commercial partnerships. Based in San Diego, California, Pfenex became part of Ligand Pharmaceuticals after Ligand completed its acquisition of the company in 2020.AI Generated. May Contain Errors. Read More Receive PFNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pfenex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PFNX Stock News HeadlinesNKY Medical Holdings Ltd Class A 300109January 31, 2024 | morningstar.comMLigand Pharmaceuticals: Struggling Along (NASDAQ:LGND) - Seeking AlphaSeptember 25, 2022 | seekingalpha.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 18 at 1:00 AM | American Alternative (Ad)Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update - Business WireAugust 15, 2022 | businesswire.comLigand Reports Second Quarter 2022 Financial Results - Business WireAugust 9, 2022 | businesswire.com2022-08-08 | NDAQ:LGND | Press Release | Ligand Pharmaceuticals Incorporated - StockhouseAugust 8, 2022 | stockhouse.comOsteoporosis Therapeutics Market to Top US$ 14 Bn Valuation by 2026: Fact.MR Analysis - Yahoo FinanceMay 17, 2022 | finance.yahoo.comLigand Reports First Quarter 2022 Financial Results - StreetInsider.comMay 5, 2022 | streetinsider.comSee More Headlines PFNX Stock Analysis - Frequently Asked Questions How have PFNX shares performed this year? Pfenex's stock was trading at $12.75 at the beginning of 2026. Since then, PFNX shares have increased by 0.0% and is now trading at $12.75. How were Pfenex's earnings last quarter? Pfenex Inc. (NYSEAMERICAN:PFNX) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.07. The biotechnology company had revenue of $680 thousand for the quarter, compared to analysts' expectations of $3.75 million. What other stocks do shareholders of Pfenex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pfenex investors own include Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Bank of America (BAC), Anheuser-Busch InBev SA/NV (BUD), Salesforce (CRM), Applied Materials (AMAT) and Advanced Micro Devices (AMD). Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:PFNX Previous SymbolNYSEMKT:PFNX CIKN/A Webwww.pfenex.com Phone+1-858-3524400FaxN/AEmployees71Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares34,297,000Free FloatN/AMarket Cap$437.29 million OptionableNot Optionable BetaN/A 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NYSEAMERICAN:PFNX) was last updated on 10/1/2020 by MarketBeat.com Staff. From Our PartnersGold Trades Near Record Highs: What It Means for MinersBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfenex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfenex With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.